GoodRx Holdings, Inc.
GDRXUnited States
39 filed reports · 359 financial concepts · 24 earnings calls · 0 media appearances
Filed reports
39 reports · Sep 2020 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 50 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 18 | 2,207 | Sep 2020 to Jun 2026 |
| Current · 8-KSEC EDGAR | 15 | 50 | Sep 2022 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 6 | 2,699 | Dec 2020 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 261 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 5, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 145 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 6, 2026 | 2 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 799 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 25, 2026 | 2 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 181 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 109 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 7, 2025 | 94 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | May 7, 2025 | 2 | Open |
| FY2024 Q4 | 8-K | Dec 31, 2024 | Feb 27, 2025 | 4 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 27, 2025 | 418 | Open |
Financial data
359 concepts · 4,956 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial354 concepts · 4,766 facts · Oct 2018 to Jun 2026
- Stockholders equity (US GAAP)39 · Dec 2018 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value38 · Dec 2018 to Jun 2026
- Net income loss38 · Dec 2018 to Jun 2026
- Cash and cash equivalents at carrying value37 · Dec 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations37 · Dec 2018 to Jun 2026
- Stock issued during period value stock options exercised37 · Dec 2018 to Mar 2026
- Cost of goods and service excluding depreciation depletion and amortization36 · Dec 2018 to Jun 2026
- Costs and expenses36 · Dec 2018 to Jun 2026
- Depreciation and amortization36 · Dec 2018 to Jun 2026
- General and administrative expense (US GAAP)36 · Dec 2018 to Jun 2026
- Income tax expense benefit36 · Dec 2018 to Jun 2026
- Incremental common shares attributable to share based payment arrangements36 · Dec 2018 to Jun 2026
- Interest income other36 · Dec 2018 to Jun 2026
- Nonoperating income expense36 · Dec 2018 to Jun 2026
- Operating income loss36 · Dec 2018 to Jun 2026
- Research and development expense36 · Dec 2018 to Jun 2026
- Revenue36 · Dec 2018 to Jun 2026
- Selling and marketing expense (US GAAP)36 · Dec 2018 to Jun 2026
- Amortization of financing costs35 · Dec 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect35 · Dec 2018 to Jun 2026
- Deferred income tax expense benefit35 · Dec 2018 to Jun 2026
- Increase decrease in accounts payable35 · Dec 2018 to Jun 2026
- Increase decrease in accounts receivable35 · Dec 2018 to Jun 2026
- Increase decrease in accrued liabilities and other operating liabilities35 · Dec 2018 to Jun 2026
Product3 concepts · 140 facts · Dec 2018 to Jun 2026
- Revenue131 · Dec 2018 to Jun 2026
- Selling expense5 · Dec 2021 to Dec 2025
- Selling and marketing expense (US GAAP)4 · Dec 2022 to Dec 2025
Guidance2 concepts · 50 facts · Nov 2022 to Aug 2026
- Revenue Guidance46 · Nov 2022 to Aug 2026
- Revenue Growth Guidance4 · Jan 2024
Segments
140 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service5 members · 140 facts
- Prescription Transactions Revenue45 · Dec 2018 to Jun 2026
- Other Revenue34 · Dec 2018 to Jun 2026
- Subscription Revenue32 · Dec 2019 to Jun 2026
- Pharma Manufacturer Solutions Revenues26 · Dec 2020 to Jun 2026
- Pharma Direct Revenue3 · Dec 2023 to Dec 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
24 calls · Nov 2020 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 5, 2026
- FY2026 Q1May 8, 2026
- FY2025 Q4Feb 26, 2026
- FY2025 Q3Nov 5, 2025
- FY2025 Q2Aug 8, 2025
- FY2025 Q1May 8, 2025
- FY2024 Q4Feb 27, 2025
- FY2024 Q3Nov 7, 2024
- FY2024 Q2Aug 8, 2024
- FY2024 Q1May 9, 2024
- FY2023 Q4Feb 29, 2024
- FY2023 Q3Nov 9, 2023
- FY2023 Q2Aug 9, 2023
- FY2023 Q1May 10, 2023
- FY2022 Q4Feb 28, 2023
- FY2022 Q3Nov 8, 2022
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.